Ethic Inc’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-11,755
Closed -$44.1K 1360
2026
Q1
$44.1K Sell
11,755
-345
-3% -$1.36K ﹤0.01% 1220
2025
Q4
$42.7K Sell
12,100
-3,107
-20% -$12.6K ﹤0.01% 1193
2025
Q3
$60.8K Sell
15,207
-22,655
-60% -$71.4K ﹤0.01% 1171
2025
Q2
$103K Buy
+37,862
New +$79.6K ﹤0.01% 1170

Other funds holding ADCT

Ethic Inc's ADCT Position: Q2 2026 in Review

Ethic Inc sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 11,755 shares — an estimated $44.1K sold.

Ethic Inc first reported a position in ADCT in Q2 2025 and held it in 4 quarters. The position peaked at $103K in Q2 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Ethic Inc reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ethic Inc sold 11,755 ADC Therapeutics shares in Q2 2026, an estimated $44.1K.
  • Ethic Inc first reported a position in ADC Therapeutics in Q2 2025 and held it in 4 quarters.
  • Ethic Inc's ADC Therapeutics position peaked at $103K in Q2 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.